Sharjah Ruler Launches First 17 Volumes of ‘Historical Corpus of the Arabic Language’
3.11.2021 18:21:00 EET | Business Wire | Press release
A historical cultural feat for the Arab world has been attained, as His Highness Sheikh Dr. Sultan bin Muhammad Al Qasimi, Member of the Supreme Council and Ruler of Sharjah, released the first 17 volumes of the Historical Corpus of the Arabic Language – the first-of-its kind project to chronicle 17 centuries of development in the Arabic language, in the presence of His Highness Sheikh Sultan bin Ahmed Al Qasimi, Crown Prince and Deputy Ruler of Sharjah.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005884/en/
HH Ruler of Sharjah signs the copies of ‘Historical Corpus of the Arabic Language’ at the Sharjah International Book Fair (Photo: AETOSWire)
The Corpus volumes were unveiled by the Sharjah Ruler during the opening ceremony of the 40th edition of the Sharjah International Book Fair (SIBF) on Tuesday (2 November) at Expo Centre Sharjah, in the presence of a host of Arab ministers, presidents of Arabic language academies in the region and several Arabic scholars and researchers. HH Ruler of Sharjah also unveiled the official website of The Historical Corpus of the Arabic Language on this occasion.
In his keynote address, the Sharjah Ruler noted: “Arabic is one of the oldest living languages. We are here to celebrate Arabic language experts who gathered to work for years to document the roots and meanings of the Arabic language alphabet. We have started to work hard and bridge the gaps that existed in the documentation of the language. Finally, the sun has risen on this beautiful Corpus, which is the fruit of the efforts of a number of Arabic language institutions across the region.”
He added: “The role this detailed corpus will play in informing and educating students, researchers, and linguists and even the everyday language enthusiasts will be immense. I am not exaggerating when I say that there has been no other project that has attracted my attention or the attention of the Arab linguist community in our region to the extent that this project has. I am following up on the development of the efforts of everyone involved in this project, and I assure you that in the coming years we will be publishing several more volumes. I thank each and everyone involved in making this project a success.”
The Sharjah Ruler spoke about the online platform and smart phone applications that have been designed to make the Historical Corpus available digitally, and facilitate easy access to these resources from anywhere in the world. He also signed the copies of the first edition of the Historical Corpus of the Arabic Language at the SIBF 2021 opening ceremony.
The first volumes of the corpus are dedicated to the first five Arabic letters: the Hamza, ba, ta, tha and jeem and outline their evolution throughout the pre-Islamic period, the Islamic era from 1 AH to 132 AH, the Abbasid Caliphate from 133 AH to 656 AH, and the modern-day era from 1214 AH to date.
Dedicated website
The website dedicated to the Historical Corpus of the Arabic Language will offer scholars, linguists, researchers and language enthusiasts access to the 17 volumes of the corpus from anywhere in the world.
Champions of the Arabic language from across the region joined hands
The corpus has seen the collaboration of hundreds of researchers and linguists, editors and experts from 10 Arabic language academies across the Arab world, under the supervision of the Union of Arab Scientific Language Academies in Cairo, Egypt, and with the Arabic Language Academy in Sharjah managing the project’s executive committee. The corpus relies on a database of sources collected and digitised over the last four years, comprising 20,000 Arabic books, manuscripts, sources, and historical documents, including old inscriptions and archaeological finds.
The Historical Corpus of the Arabic Language is dedicated to providing key information about the history of Arabic lexicon, the original root of each word and all other words that are derived from the root with their vocal and phonetic changes. It traces the history of a given word and identifies the first user and evolution of that word from pre-Islamic Arabia all the way to the modern time. In this respect, it is different from any other dictionary because it cites living verses of the Holy Quran and Hadith of the Prophet, peace be upon him.
It also reveals the development of Arabic idioms and expressions through the centuries, and documents the entry of new words into Arabic language, lists words that are no longer used, and explains the reasons why. Besides, the corpus reviews the development of arts and sciences that directly relate to linguistics including grammar, morphology, philology, phonetics, rhetoric, rhyme, and so on.
It also offers comparative lexical reviews on Arabic and the influence it had on other Semitic languages such as Hebrew, Akkadian, Syriac, Abyssinian, and Amharic. An expert committee outlined the similarities and differences between Arabic words and the equivalent words in those languages, citing examples and documenting the bibliography and reference books that were used in the project.
Several senior officials were present during the launch, including Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister of Tolerance and Coexistence; Bodour Al Qasimi, President of the International Publishers Association; Sheikha Hoor Al Qasimi, President of the Sharjah Art Foundation; Sheikh Khalid bin Issam Al Qasimi, Chairman of the Department of Civil Aviation in Sharjah; Sheikh Salem bin Abdulrahman Al Qasimi, Chairman of the Sharjah Ruler's Office; Sheikha Nawar bint Ahmed Al Qasimi, Director, SAF; Abdul Rahman bin Mohammad Al Owais, UAE Minister of Health and Prevention.
The launch of the corpus’s 17 volumes was also witnessed by Dr. Salah Fadl, President of the Arab Language Academy in Cairo; Dr. Mamoun Wajeeh, Scientific Manager of the Historical Corpus of the Arabic Language; Dr. Abdulhamid Madkour, Secretary General of the Union of Arab Scientific Language Academies, and Secretary-General of the Arabic Language Academy in Cairo.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005884/en/
Contact information
Hussain Al Mulla
Email: hussain.almulla@sgmb.ae
Phone: +97156 3980067
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
